All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
Details:
The claims of this new patent build on the protection provided by the parent patent, and are directed to methods of treating cancer by administering Immutep‘slead active immunotherapy candidate eftilagimod alpha and a PD-1 pathway inhibitor.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
Immutep has enrolled and safely dosed the last patient for stage 2 of Part C of its TACTI-002 Phase II study. Completes recruitment of patients with 2nd line head and neck squamous cell carcinoma. Recruitment of additional 1st line non small cell lung cancer patients started.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: Efti
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2020
Details:
The claims of the patent protect Immutep’s intellectual property relating to combined preparations comprising its lead active immunotherapy candidate eftilagimod alpha (“efti” or “IMP321”) and a PD-1 pathway inhibitor.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Details:
The Phase IIb AIPAC study is evaluating Immutep’s lead product candidate eftilagimod alpha in combination with paclitaxel chemotherapy in comparison to a combination of placebo and paclitaxel chemotherapy in patients with HER2-negative/HR positive metastatic breast cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Australian Ethical
Deal Size: $22.4 million Upfront Cash: Undisclosed
Deal Type: Financing November 19, 2020
Details:
The Company will use the proceeds to finance its LAG-3 related clinical program in immuno-oncology and autoimmune disease. The funds will also be used for the cell-line development of IMP761, R&D, manufacturing, the offering costs and working capital purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Paxalisib
Therapeutic Area: Oncology Product Name: GDC-0084
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
The new interim analysis of paxalisib phase II study in glioblastoma is highly consistent with prior data. Median progression-free survival (PFS) of 8.4 months reported on this analysis (versus 5.3 months for temozolomide, the existing standard of care).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: Efti
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
The study is evaluating combination of efti with MSD’s KEYTRUDA® (pembrolizumab) in up to 109 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2020
Details:
More mature interim data from phase II TACTI-002 study of eftilagimod alpha has been accepted as a late breaker poster presentation and poster walk for highly scored abstracts at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
